Genmab Continues Share Buy-back Program Amid Strategic Financial Management

Genmab ( (GMAB) ) has shared an announcement.

On June 2, 2025, Genmab A/S announced the continuation of its share buy-back program, initially launched on March 25, 2025, to repurchase up to 2.2 million shares. The program, which aims to reduce capital and fulfill commitments under the Restricted Stock Unit program, executed transactions from May 26 to May 30, 2025, and is expected to conclude by July 10, 2025. Following these transactions, Genmab holds 2,531,638 shares as treasury shares, representing 3.95% of the total share capital and voting rights. This strategic move is aligned with Genmab’s financial management goals and may impact its market positioning by optimizing capital structure.

The most recent analyst rating on (GMAB) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.

Spark’s Take on GMAB Stock

According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.

Genmab exhibits strong financial performance with consistent profitability and low leverage. The company’s robust pipeline and strategic investments support future growth. However, technical analysis indicates neutral momentum, and dependency on key products introduces some risk.

To see Spark’s full report on GMAB stock, click here.

More about Genmab

Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. Established in 1999, the company has a strong presence across North America, Europe, and Asia Pacific, and aims to transform the lives of patients with cancer and other serious diseases through advanced antibody medicines.

Average Trading Volume: 1,519,416

Technical Sentiment Signal: Sell

Current Market Cap: $12.93B

Learn more about GMAB stock on TipRanks’ Stock Analysis page.